Why this page exists
Most of the posts on this site touch a regulatory question at some point. Until recently I was leaving a generic three-line disclaimer at the bottom of each post, which said roughly "no exosome products are FDA-approved, most stem cell therapies are not approved, this is educational only." That was true enough in spirit, but the landscape changed quickly between when I first wrote it and now. There are several FDA-approved cellular therapies now (just not for the indications most of this site discusses). Florida passed a law in 2025 that specifically opens up orthopedic and pain-management stem cell uses. The federal-state tension has been litigated. A short post disclaimer can't carry all of that, so the disclaimers now link here.
This is what I actually understand to be true as of May 2026. It is not legal advice. The law in this area is moving — verify with a healthcare-regulatory attorney before making any decision that turns on it.
The federal framework: 21 CFR 1271
In the United States, cellular and tissue-based products are regulated by the FDA under 21 CFR Part 1271. That rule creates a two-track classification system for what FDA calls HCT/Ps — Human Cells, Tissues, and Cellular and Tissue-Based Products.
"361" products — lighter pathway
A product is regulated solely under Section 361 of the Public Health Service Act and 21 CFR 1271 if it meets all four of the criteria in 21 CFR 1271.10(a):
- Minimally manipulated — the processing doesn't alter the tissue's original relevant characteristics.
- Intended for homologous use only — same basic function in the recipient as in the donor.
- Not combined with another article, with narrow exceptions for water, crystalloids, and sterilizing/preserving/storage agents.
- No systemic effect and not dependent on the metabolic activity of living cells — except for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.
If all four are met, the manufacturer only has to register with FDA, list the product, screen donors, and follow current good tissue practice. No premarket approval is required. No IND, no BLA. This is the path for things like minimally processed bone allografts and standard tissue products.
"351" products — full biologic drug pathway
Anything that misses even one of those four criteria becomes a "351" product — a "biological product" under Section 351 of the Public Health Service Act (42 U.S.C. § 262) and a "drug" under the FD&C Act. That means an Investigational New Drug (IND) application to begin clinical investigation, and a Biologics License Application (BLA) before lawful commercial distribution. Years of trials. Tens to hundreds of millions of dollars.
What this means at the bedside
A few practical examples, with citations to the court rulings that established them:
- Harvesting a patient's bone marrow aspirate and reinjecting it in the same operative session — typically fits the 21 CFR 1271.15(b) same surgical procedure exception. Outside Part 1271 entirely.
- Culture-expanding mesenchymal stem cells in a lab before reinjecting them — more than minimal manipulation; falls under 351. United States v. Regenerative Sciences (D.C. Cir. 2014).
- Enzymatically digesting fat tissue to produce stromal vascular fraction (SVF) and injecting it for non-orthopedic indications — more than minimal, and non-homologous. Two appellate courts have held this is a 351 biologic that requires FDA approval: US Stem Cell Clinic (11th Cir. 2021) and California Stem Cell Treatment Center (9th Cir. 2024).
- Any allogeneic (donor-derived) product — Wharton's jelly, amniotic fluid, placental cells, exosomes derived from any of those — for non-homologous orthopedic, neurologic, or anti-aging use: FDA treats virtually all of these as unapproved 351 biologics.
What's actually FDA-approved (and what isn't)
The disclaimer this page replaces used to say "only hematopoietic stem cell transplants are FDA-approved." That was already incomplete in 2025 and is meaningfully wrong now. As of May 2026, the FDA-approved universe of cellular and gene therapies includes:
- Hematopoietic stem cell transplantation (HSCT) for hematologic malignancies and certain inherited disorders.
- Licensed cord-blood units for hematopoietic reconstitution under multiple BLAs.
- CAR-T cell therapies — at least seven approved, including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl (Nov 2024). Most recent label expansion: Breyanzi for relapsed/refractory marginal-zone lymphoma, December 4, 2025.
- Gene-edited hematopoietic stem cell therapies for sickle-cell disease — Casgevy (exa-cel) and Lyfgenia, both approved December 2023.
- Ryoncil (remestemcel-L) — the first FDA-approved mesenchymal stem cell product, approved December 2024 for pediatric steroid-refractory acute graft-versus-host disease.
- Other approved cellular immunotherapies — Provenge (sipuleucel-T) and Amtagvi (lifileucel, 2024) for melanoma.
The FDA's running list lives at Approved Cellular and Gene Therapy Products. It updates as new approvals come through.
What this list does not include: any FDA-approved cellular or exosome product for the indications most of this site discusses — hypermobile EDS, MCAS, POTS, dysautonomia, orthopedic joint and tendon repair, autoimmune disease, anti-aging, "longevity." In every one of those use cases, the product is either being administered in a clinical trial, under a state carve-out (see below), or outside the regulated system. The first two carry meaningful oversight. The third carries the risks every unregulated cellular therapy carries — source unknown, dose unknown, processing unknown.
Exosomes — a separate, sharper picture
The FDA's Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes says, in language verbatim from the page:
"Exosome products intended to treat diseases or conditions in humans require FDA approval, and there are currently no FDA-approved exosome products."
Two follow-on FDA pages worth knowing about: the Public Safety Notification on Exosome Products and the Patient and Consumer Warning on unapproved cellular products generally.
FDA has continued to issue warning letters to clinics marketing exosomes. New Life Medical Services (Sept 2025), Supreme Rejuvenation (May 2025), and roughly a dozen others through 2025. None of the state carve-outs covered below extend to exosomes. Every state stem-cell statute is written narrowly around stem cells; exosomes remain unapproved 351 biologics everywhere in the U.S.
Cosmetic exosomes — the qualifier worth knowing
Everything above is about therapeutic exosomes — products injected (IV, intra-articular, intra-tissue) or otherwise marketed to treat, prevent, or affect the structure or function of the body. A narrower regulatory space exists for topical cosmetic exosomes — exosomes in serums, creams, and similar products marketed for "beautifying" or "improving appearance" without any therapeutic claim.
In the U.S., cosmetics do not require FDA premarket approval at all. They are regulated under a different and much lighter regime — labeling rules, manufacturing safety, ingredient safety — but they do not go through the IND/BLA pathway. So when you read "no FDA-approved exosome products," the more precise statement is "no exosome product has FDA approval for therapeutic use; topical cosmetic exosomes sit in a different regulatory regime that does not require FDA approval to begin with." The right question for any specific product is not "is it FDA-approved?" but "what is this product being used for, and what regime does that use sit under?"
One area where the regulatory line is genuinely contested in practice: exosomes used in or after microneedling and similar procedures. FDA has taken the position that when an exosome product is paired with a delivery mechanism that bypasses the skin barrier, the product is being administered as a drug or biologic regardless of cosmetic positioning, and the agency has issued some 2024–2025 warning letters to clinics offering exosome-microneedling specifically. In actual practice, the use of topical exosomes in microneedling and post-procedural skincare contexts is widespread, and the regulatory line is being worked out in real time rather than settled. This site doesn't take a position on what individual providers should or shouldn't do in that gray zone — that's a conversation between providers, their own counsel, and their patients. The honest description is that FDA's stated position and the broader practical landscape are not the same thing.
Rough orientation for the kinds of products this site discusses:
- Pure topical exosome skincare (serum, cream, mist applied to intact skin without a delivery device): cosmetic regime, FDA approval not required.
- Topical exosomes used in or around microneedling, lasers, or other skin-barrier-affecting procedures: widely practiced; FDA has expressed concerns and issued some warning letters in this space; the regulatory characterization is contested. A practical question for any patient considering it is what their provider's own counsel and the manufacturer of the product say about how it's intended to be used.
- Injected exosomes (IV, intra-articular, mesotherapy injection): unambiguously an unapproved 351 biologic. No FDA approval exists for any indication.
State carve-outs
Four U.S. states have passed laws creating specific permission frameworks for certain non-FDA-approved stem cell therapies. None of these statutes address exosomes. None of them insulate providers from federal FDA enforcement (more on that below). What they do is permit a provider to administer specified therapies under defined conditions without violating state medical-practice rules.
Texas — H.B. 810, "Charlie's Law"
Signed by Governor Abbott in 2017, effective September 1, 2017. Codified at Texas Health & Safety Code Chapter 1003, Subchapter B (§§ 1003.051–.058). Bill text here.
Permits a Texas physician to administer investigational stem cell treatment outside an FDA-approved trial only if:
- The patient has a severe chronic disease or terminal illness;
- FDA-approved options have been exhausted;
- The treatment is IRB-overseen;
- It is administered at a hospital or medical school;
- It is delivered by an IRB-certified physician;
- The patient has provided written informed consent.
Charlie's Law does not authorize exosomes. It does not preempt FDA. Its practical use to date has been narrow.
Florida — S.B. 1768
Signed into law in 2025, Chapter Law 2025-185, effective July 1, 2025. Codified at Fla. Stat. §§ 458.3245 (M.D. version) and 459.0127 (D.O. version). Bill page here.
This is the state law most relevant to readers of this site, because it specifically permits non-FDA-approved stem cell therapy for orthopedic, wound care, and pain management indications — the categories most regenerative-medicine practice falls into. Requirements:
- Cells must be processed at FDA-registered and accredited facilities (NMDP, WMDA, AABB, or AATB);
- Cells must be ethically sourced — post-live-birth placental and cord blood is permitted; aborted-fetal tissue is prohibited;
- Written informed consent is required;
- Advertising must include specific disclosure language.
The Florida statute does not extend to exosomes.
Utah — S.B. 199
Passed in 2024. Codified at Utah Code § 58-1-512. Bill text here.
The broadest of the four state laws. Permits many provider categories to administer non-FDA-approved placental and perinatal stem cell therapy with only written notice and informed consent — narrower disease and procedural conditions than Texas or Florida. Worth reading the statute directly before relying on it.
Mississippi — S.B. 2830
Passed in 2020. Folds autologous mesenchymal stem cells into the state's broader Right-to-Try framework. Narrower than the other three; specific to autologous use.
Other states
Several other states have considered or partially implemented similar legislation — Montana, North Carolina, Tennessee, New Hampshire, and Wyoming have been mentioned in secondary surveys. None has, to my knowledge, enacted a stem-cell-specific statute as developed as the four above. Verify with current state-level counsel before relying on any of them.
The federal–state tension
This is the part where the practical answer for any specific patient gets complicated.
The FDA's longstanding position is that federal law preempts state law for biologic products. A state statute that permits a clinic to administer something the FDA considers an unapproved 351 biologic does not actually shield the clinic from federal enforcement. It shields them from state medical-board discipline based on the practice itself, but the FDA can still bring an injunction or refer for criminal prosecution.
The FDA has won every major appellate test of its authority in this area:
- United States v. Regenerative Sciences (D.C. Cir. 2014) — culture-expanded MSCs are 351 biologics.
- United States v. US Stem Cell Clinic (11th Cir. 2021) — SVF for non-homologous use is a 351 biologic.
- United States v. California Stem Cell Treatment Center (9th Cir. 2024) — same.
SCOTUS denied certiorari on the California Stem Cell Treatment Center case on October 14, 2025, leaving the Ninth Circuit ruling in place. No state has yet directly defended one of its stem-cell statutes against an FDA preemption challenge in federal court.
The FDA continues to issue warning letters to providers operating in permissive states. Recent enforcement targets in Arizona, Nevada, Florida, and California demonstrate that state permission does not deter federal action.
What this means for you, practically
Depending on where you are and what indication you're being treated for, a provider may be operating under one of:
- Full FDA approval (rare for the indications this site discusses);
- An active FDA-registered clinical trial (some oversight; the right path if a relevant trial is open and you qualify);
- A state carve-out (Texas, Florida, Utah, Mississippi — meaningful in-state, but does not insulate from federal action);
- The same-surgical-procedure exception in 21 CFR 1271.15(b) — autologous, minimally manipulated, same-session;
- None of the above — i.e., outside the regulated system.
Any of the first four can be reasonable depending on the patient and the indication. The fifth is where almost all of the patient-safety problems documented in the cellular-therapy literature originate.
Things worth asking any provider you're evaluating, in plain language:
- Under which regulatory pathway are you administering this — FDA approval, clinical trial, state law, same-surgical-procedure exception, or none?
- What product, specifically? Manufacturer, lot characterization data, certificate of analysis?
- If you cite a state law, which statute specifically, and have you verified it applies to this indication?
- If you are operating outside FDA approval, are you aware of FDA's enforcement posture and how that affects continuity of care for me?
A provider who can answer those clearly is operating with the kind of awareness you want from someone injecting something into your body. A provider who can't, or who dismisses the question, is telling you something useful about how they think about risk.
When this page gets updated
The legal landscape moves fast. I update this page when one of the following happens: a state passes new stem-cell or exosome legislation; FDA issues a major guidance change or warning-letter campaign; a federal court ruling materially changes the preemption picture; an FDA-approved cell therapy lands for one of the indications this site discusses.
Current as of May 23, 2026. If you are reading this much later, the specifics may have moved. Verify the citations above against current law.
Not medical, legal, or regulatory advice. Verify with a qualified healthcare-regulatory attorney before relying on any of this.